SAN DIEGO, March 16, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has invested in seven new genomics companies to join the fourth global funding cycle of Illumina Accelerator San Francisco Bay Area and Cambridge, UK. The global company creation engine is focused on partnering with entrepreneurs to build breakthrough genomics startups and its next global funding cycle application deadline is April 1, 2022.
Illumina Accelerator is accepting applications this month for its next global cohort of genomics startups, the deadline is April 1.
"A hands-on company creation engine and venture…
Monument Tx CSO to present novel biomarker predicting risk for developing POCD at AD/PD conference in Barcelona 15-20th March 2022
Manchester, UK, March 14, 2022: Monument Therapeutics, a stratified medicine company, today announced it will be presenting data to support their novel biomarker that can predict risk of an individual developing Post-Operative Cognitive Decline (POCD), at the AD/PD conference, 15-20th March 2022. Findings will be presented from the analysis of a large European dataset that included over 1000 patients that were cognitively and clinically assessed both before and…
Monument Tx CSO to present preclinical data for lipid reformulation of anti-inflammatory compound MT1980 at AD/PD conference in Barcelona 15-20th March 2022
Manchester, UK, March 14, 2022: Monument Therapeutics, a stratified medicine company, today announced it will be presenting their positive preclinical results for MT1980, a lipid-based reformulation of an on-market anti-inflammatory compound, at the AD/PD conference, 15-20th March 2022. Findings will be presented from preclinical pharmacokinetic and pharmacodynamic experiments that support the development of MT1980 for a range of major…
SCIENCE AND INNOVATION SECTORS IN CAMBRIDGE DRIVE GROWTH IN REGIONAL EMPLOYMENT DESPITE PANDEMIC TURBULENCE
Information technology, telecommunications, and the life sciences remain the largest and most dynamic of the knowledge intensive sectors
Cambridge, UK. 15th March 2022: New data covering the first full year of the pandemic (April 2020 to March 2021) shows the striking resilience of the Cambridge area to pandemic shocks. It reveals that the innovation clusters in the Cambridge city region – particularly Life Sciences and Information Technology – were the driving force of the local…
• The Lab Hotel provides free laboratory and office accommodation for start-up companies for six months.
• Applications to join the Lab Hotel are welcome from start-ups working in advanced therapeutics and drug discovery.
• Companies in the Lab Hotel have access to scientific and business support while they develop their innovations and secure their next round of funding.
Stevenage Bioscience Catalyst (SBC) is offering free lab and office accommodation for start-ups – and space is available now. In addition to free accommodation, Lab Hotel occupiers receive scientific and business support,…
Coventry, United Kingdom, 10th March 2022 / NanoSyrinx, a biotech company using synthetic biology approaches to develop a new modality for the targeted intracellular delivery of biologic therapeutics, has strengthened its management team with the appointment of Dr Marie McAvoy as its Chief Scientific Officer.
Dr McAvoy joins NanoSyrinx from GSK where she was Senior Director in the Oncology Cell Therapy Research Unit. She brings more than 20 years of drug discovery experience in biotech and large pharma companies, having worked on vaccines, biopharmaceuticals and cell and gene therapies, and…
Huge demand for commercial lab and office space at Newcastle’s Biosphere means private sector investment is now being sought to take the lead on expanding the heart of the north east’s £1.7bn life science eco-system.
Located at Newcastle Helix, The Biosphere launched in 2019 as a publicly funded project, led by Newcastle City Council; it represented a significant investment for the local economy and showed a clear commitment to life sciences growth.
Potential investors from across the world will have the opportunity to find out more when Invest Newcastle (part of NewcastleGateshead…
Cambridge, UK, 7th March 2022 – Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date.
The international investment syndicate was co-led by Flerie Invest, a major Swedish life science investor focussing on companies with ambitious science and the ability to tackle major medical challenges, and Tencent, a global technology company investing in innovations that help improve human life. New…
Cambridge, United Kingdom, 3rd March 2022 / Sciad Newswire / Domainex Ltd., a leading integrated medicines research services partner, announces that it has purchased over £1M worth of new Waters equipment to enhance its capabilities in analytical chemistry, bioanalytical sciences and in vitro absorbance, distribution, metabolism and excretion (ADME) assays. The new equipment will allow Domainex to increase its capacity and throughput, supporting its ongoing growth.
Included in the new equipment are two ACQUITY UPLC systems (one with an evaporative light scattering detector (ELSD) and one with…
https://blogs.deloitte.co.uk/health/2022/02/how-genomics-is-transformin…
In September 2021, to mark the first anniversary of the Deloitte Life Sciences Catalyst, we were privileged to attend an insightful hybrid webinar on The Future of Genomics.1 The webinar, chaired by Deloitte partner Mike Standing, was introduced by Frances Cousins who leads the Catalyst, and featured the following esteemed panellists: Professor Dame Sue Hill (Chief Scientific Officer for England), Dr David Bentley (Chief Scientific Officer of Illumina), Dr David Atkins (Chief Executive Officer of Congenica), Dr Julia…